Antihypertensive treatment and multifactorial approach for renal protection in diabetes

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Fioretto, Paola ^a,c   Solini, Anna ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; IRBESARTAN; LIPOPROTEIN; LISINOPRIL; LOSARTAN; PLACEBO; STATIN; TELMISARTAN; VALSARTAN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RISK FACTOR; SMOKING CESSATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION TEST; MALE; METHODOLOGY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20844451529     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110962     Document Type: Conference Paper

References (25)

1. Parving H-H, Mauer M, Ritz E: Diabetic nephropathy. In: Brenner and Rector's the Kidney, 7th Ed., edited by Brenner BM, Philadelphia, WB Saunders, 2004, pp 1777-1818
2. The EUCLID Study Group: Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792, 1997
3. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713, 1998
4. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and Micro-HOPE substudy. Lancet 355: 253-259, 2000
5. Schrier RW, Estacio RO, Esler A, Meheler P: Effects of aggressive blood pressure in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086-1097, 2002
6. Estacio RO, Jeffers BW, Gifford N, Shrier N: Effect of blood pressure control on microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23[Suppl 2]: B54-B64, 2000
7. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes and microalbuminuria receive angiotensin- converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134: 370-379, 2001
8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
9. Viberti G, Wheeldon NM; for the MARVAL Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: Blood pressure independent effect. Circulation 106: 672-678, 2002
10. Deferrari G, Ravera M, Berruti V: Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev 19: 101-114, 2003
11. Lewis E, Hunsicker L, Bain R, Rohode RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snappin SN, Zhang Z, Shahinfar S: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohode R, Raz I: Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
14. Molich ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW: Diabetic nephropathy. Diabetes Care 27: S79-S83, 2004
15. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J: DETAIL Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004
16. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
17. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
18. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
19. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
20. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia: A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 45: S125-S131, 1994
21. Hsu CY, Bates DW, Kuperman GJ, Curhan GC: Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 36: 272-281, 2000
22. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, Floege J: Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11: 669-683, 2000
23. Sahadevan M, Kasiske BL: Hyperlipidemia in kidney disease: Causes and consequences. Curr Opin Nephrol Hypertens 11: 323-329, 2002
24. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353: 617-622, 1999
25. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003